In addition, the therapeutic efficacies of ALK inhibitors in prolonging the PFS of the overall patients with ALK-p, ALK inhibitor-naïve advanced NSCLC and a subgroup of patients with CNS metastases are compared by drug and by generation. The gene discussed is ALK; the disease is non-small cell lung carcinoma.